Phaseline

Targets › HAMP

HAMP (Hepcidin): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Oct 2027.

Liver-produced hormone that constitutes the main circulating regulator of iron absorption and distribution across tissues. Acts by promoting endocytosis and degradation of ferroportin/SLC40A1, leading to the retention of iron in iron-exporting cells and decreased flow of iron into plasma. (UniProt, P81172)

Open in Phaseline: the race on HAMP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaRusfertide
Hepcidin mimetic
HAMPPhase 2Polycythemia VeraOct 2027

Conditions

Polycythemia Vera (1)

Modalities

protein or peptide (1)

Companies

Takeda (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.